Phase 2 N=26 Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=25 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Advanced Cancer
Primary: Treatment-related Adverse Events — 19; 103; 85 Number of Treatment-related Adverse Even
Phase 3 N=5 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
Metastatic Lung Cancer · Stage IV Lung Cancer
Primary: Number of Participants With Progression-free Survival (PFS) After Completion of First Line Standard of Care Systemic Therapy — 1; 0 Participants
N/A N=35 Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer Metastatic
Primary: Time to Best Overall Response — 14 months
Phase 2 N=58 Allergy Immunotherapy for the Reduction of Asthma
Wheezing · Asthma · Allergy
Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38
Phase 2 N=64 Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate (DCR) After 12 Weeks Induction — 0.742 proportion of participants
Phase 2 N=56 Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Metastatic Castration Resistant Prostate Cancer · Metastatic Cancer · Solid Tumor
Primary: The Proportion of Patients With CDK12 Loss of Function Metastatic CRPC That Respond to Treatment. — 2; 0 participants
Phase 2 N=25 The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial
Non-small Cell Lung Cancer, NSCLC
Primary: Progression-Free Survival (PFS) — 19 Participants
Phase 1 N=39 Immunotherapy of Stage III/IV Melanoma Patients
Melanoma
Primary: Change From Baseline in Mean Number of Adverse Events (Serious and Non Serious Events) — 13.40; 18.40; 23.80; 19.60 Number of adverse events
Phase 2 N=15 Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Phase 2 N=33 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Metastatic Melanoma
Primary: Number of Participants With Treatment-related Grade 3-5 Adverse Events in Arm 1N and Arm 1P — 0; 2; 0; 0 Participants
N/A N=9 Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)
Breast Cancer · Upper Extremity Lymphedema
Primary: Volume Changes as Measured by Perometry
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Phase 2 N=44 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
Phase 2 N=75 Priming Immunotherapy in Advanced Disease With Radiation
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Phase 2 N=30 Neoadjuvant Pembrolizumab
Non-small Cell Lung Carcinoma
Primary: Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab — 24 Participants
N/A N=26 Immunotherapy of the Paraneoplastic Syndromes
Paraneoplastic Syndromes
Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months
Phase 2 N=113 Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
Metastatic Androgen Independent Prostate Cancer
Primary: Safety of APC8015F by Review of Reported Adverse Events — 109 Participants
N/A N=30 Oral Peanut Immunotherapy
Peanut Allergy
Primary: Tolerance or Sustained Unresponsiveness — 2; 7 Participants
Phase 4 N=275 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
Allergic Asthma
Primary: Number of Participants With Systemic Allergic Reactions (SAR) to Specific Immunotherapy (SIT) — 32; 17; 49 participants
Phase 2 N=46 Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 77.1 percentage of participants
Phase 2 N=67 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Cancer of Head and Neck · Head and Neck Cancer · Neoplasms, Head and Neck
Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants
N/A N=31 Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy
Asthma
Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units
Phase 1 N=11 Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Treatment-related Adverse Events (AEs) — 0; 0; 0; 0 Events
Phase 3 N=789 Study of Immunotherapy to Treat Advanced Prostate Cancer
Prostate Cancer
Primary: Overall Survival (OS) — 11.04; 10.02 months — p=0.0127
Phase 2 N=23 Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Evaluate Toxicity of Infusing HER2-specific T Cells as Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 — 0…
N/A N=45 Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)
Stage IV Non-Small Cell Lung Cancer
Primary: Progression-free Survival — 26 Participants — p=0.0007
N/A N=20 Immunological Response After Shrimp Oral Immunotherapy Treatment
Allergy to Shrimp · Immunotherapy
Primary: Change in Eliciting Dose of Shrimp During Oral Food Challenge — 3233; 25 mg
Phase 2 N=36 Effect of Intralymphatic Immunotherapy
Allergy · Immune Tolerance · Injection Site Discomfort
Primary: Change in cSMS (Combined Symptom and Medication Score) — 2.6; 2.3; 4.5 score on a scale
Phase 2 N=20 Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
Advanced Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Metastatic Head-and-neck Squamous-cell Carcinoma
Primary: Overall Response - — 40.0 percentage of participants